Are we in an AI biotech bubble?

A significant merger between AI-driven drug discovery firms Recursion Pharmaceuticals and Exscientia has raised questions regarding the future of AI in the biotech sector. As both companies’ market value decreased prior to the merger, insiders question whether this reveals a potentially bursting AI biotech bubble or a market correction. Experts argue the downturn is due to a mismatch between lack of significant AI breakthroughs in drug discovery and high expectations.